Isomorphic Labs, the AI drug discovery firm spun out of Google DeepMind, is in advanced talks to raise over $2 billion in a new funding round, Bloomberg reported. Venture firm Thrive Capital, which led its first funding round, is expected to lead this investment as well. Google parent Alphabet is also set to participate in the round.